ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. A conference call and live webcast at 8:00 a.m. ET will discuss the results, with replay available for 12 months.
Executives on the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. The webcast and replay will be available under Investors > Events and Presentations at www.anipharmaceuticals.com. Dial-in details include toll-free U.S. access and Conference ID 5230834.
Positive
- None.
Negative
- None.
News Market Reaction – ANIP
In the Feb 13 session, ANIP gained 0.86%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 07 | Record Q3 2025 results | Positive | +0.2% | Record Q3 revenues and earnings with raised 2025 guidance. |
| Oct 24 | Q3 2025 call date | Neutral | -0.7% | Announcement of Q3 2025 results release and conference call details. |
| Aug 08 | Record Q2 2025 results | Positive | +18.1% | Record Q2 revenues, strong Rare Disease growth, guidance raised. |
| Aug 01 | Q2 2025 call date | Neutral | +0.9% | Scheduling of Q2 2025 results release and earnings call access details. |
| May 09 | Record Q1 2025 results | Positive | -7.3% | Record Q1 revenues, strong Rare Disease and Generics growth, guidance raised. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases with strong results and guidance have often seen positive price reactions, while one strong quarter previously saw a negative reaction.
Over 2025, ANIP reported record Q1–Q3 2025 results with rising revenues and multiple guidance raises, especially driven by Rare Disease and Cortrophin Gel. Earnings call scheduling releases in May, August, and October 2025 produced modest, mixed price moves, while the actual results (Q1–Q3) generally supported a growth narrative. Today’s announcement simply schedules the fourth quarter and full-year 2025 results call, following a year of record performance and raised outlook.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:
| Date | Friday, February 27, 2026 |
| Time | 8:00 a.m. ET |
| Toll free (U.S.) | 800-274-8461 |
| Conference ID | 5230834 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 12 months following the event.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com
